CSIMarket
 


Pacira Biosciences inc   (PCRX)
Other Ticker:  
 

Pacira Biosciences Inc 's Working Capital Ratio

PCRX's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth


Pacira Biosciences Inc 's Current Assets grew by 4.18 % in the III Quarter 2023 sequentially, while Current Liabilities decreased, this led to improvement in Pacira Biosciences Inc 's Working Capital Ratio to 4.78, above Pacira Biosciences inc average Working Capital Ratio.

Within Major Pharmaceutical Preparations industry 251 other companies have achieved higher Working Capital Ratio than Pacira Biosciences Inc in third quarter 2023. While Working Capital Ratio total ranking has improved so far during the III Quarter 2023 to 993, from total ranking in the second quarter 2023 at 1323.

Explain Working Capital Ratio
How much in Current Assets PCRX´s has?
What is the value of PCRX´s Current Liabilities?


PCRX Working Capital Ratio (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities Change -28.79 % -18.22 % -67.65 % -71.64 % -41.75 %
Y / Y Current Assets Change -16.15 % -18.41 % -43.61 % -42.46 % -35.14 %
Working Capital Ratio MRQ 4.78 3.94 3.81 3.37 4.06
PCRX's Total Ranking # 993 # 1323 # 1436 # 1737 # 1637
Seq. Current Liabilities Change -14 % 10.35 % -33.21 % 12.35 % -1.24 %
Seq. Current Assets Change 4.18 % 14.15 % -24.53 % -6.58 % 1.37 %



Working Capital Ratio third quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 252
Healthcare Sector # 459
Overall Market # 992


Working Capital Ratio Statistics
High Average Low
10.89 4.46 0.82
(Mar 31 2013)   (Mar 31 2014)




Financial Statements
Pacira Biosciences Inc 's Current Liabilities $ 94 Millions Visit PCRX's Balance sheet
Pacira Biosciences Inc 's Current Assets $ 447 Millions Visit PCRX's Balance sheet
Source of PCRX's Sales Visit PCRX's Sales by Geography


Cumulative Pacira Biosciences Inc 's Working Capital Ratio

PCRX's Working Capital Ratio for the trailling 12 Months

PCRX Working Capital Ratio

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities TTM Growth -28.79 % -18.22 % -67.65 % -71.64 % -41.75 %
Y / Y Current Assets TTM Growth -16.15 % -18.41 % -43.61 % -42.46 % -35.14 %
Working Capital Ratio TTM 3.9 3.77 3.78 3.1 2.38
Total Ranking TTM # 717 # 3994 # 4037 # 3478 # 3488
Seq. Current Liabilities TTM Growth -14 % 10.35 % -33.21 % 12.35 % -1.24 %
Seq. Current Assets TTM Growth 4.18 % 14.15 % -24.53 % -6.58 % 1.37 %


On the trailing twelve months basis Current Liabilities decreased faster than Pacira Biosciences Inc 's average Current Assets, this led to increase in in Pacira Biosciences Inc 's Working Capital Ratio to 3.9, Working Capital Ratio remained below PCRX average.
Working Capital Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 238 other companies have achieved higher Working Capital Ratio than Pacira Biosciences Inc . While Working Capital Ratio overall ranking has improved so far to 717, from total ranking during the twelve months ending second quarter 2023 at 3994.

Explain Working Capital Ratio
How much in Current Assets PCRX´s has?
What is the value of PCRX´s Current Liabilities?

TTM Working Capital Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 239
Healthcare Sector # 438
Within the Market # 717


trailing twelve months Working Capital Ratio Statistics
High Average Low
8.42 3.94 1.07
(Mar 31 2019)   (June 30. 2014)




Companies with similar Working Capital Ratio in the quarter ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Working Capital RatioSep 30 2023 MRQ Current AssetsSep 30 2023 MRQ Current Liabilities
Io Biotech Inc   12.96 $ 168.254  Millions$ 12.985  Millions
Relmada Therapeutics Inc   12.95 $ 109.101  Millions$ 8.422  Millions
Prothena Corporation Public Limited Company  12.94 $ 690.604  Millions$ 53.370  Millions
Chimerix Inc   12.94 $ 200.622  Millions$ 15.510  Millions
Anebulo Pharmaceuticals Inc   12.63 $ 9.048  Millions$ 0.717  Millions
Biomea Fusion Inc   12.49 $ 202.504  Millions$ 16.210  Millions
Ovid Therapeutics Inc   12.33 $ 91.713  Millions$ 7.439  Millions
Cryoport inc   12.27 $ 550.796  Millions$ 44.905  Millions
Oric Pharmaceuticals Inc   12.26 $ 232.236  Millions$ 18.944  Millions
Sensei Biotherapeutics Inc   11.86 $ 73.836  Millions$ 6.226  Millions
Mei Pharma Inc   11.78 $ 88.422  Millions$ 7.509  Millions
Ventyx Biosciences Inc   11.76 $ 308.092  Millions$ 26.208  Millions
Protagonist Therapeutics inc   11.66 $ 324.881  Millions$ 27.867  Millions
Cormedix Inc   11.61 $ 89.062  Millions$ 7.671  Millions
Erasca Inc   11.45 $ 305.966  Millions$ 26.730  Millions
Anaptysbio Inc   11.43 $ 428.000  Millions$ 37.437  Millions
Uniqure N v   11.42 $ 693.626  Millions$ 60.719  Millions
Avidity Biosciences Inc   11.40 $ 555.487  Millions$ 48.716  Millions
Caladrius Biosciences Inc   11.15 $ 57.233  Millions$ 5.132  Millions
Atai Life Sciences N v   11.12 $ 215.825  Millions$ 19.403  Millions
Pasithea Therapeutics Corp   11.11 $ 20.771  Millions$ 1.869  Millions
Lipocine Inc   10.98 $ 24.614  Millions$ 2.241  Millions
Nkarta Inc   10.97 $ 281.188  Millions$ 25.640  Millions
Kinnate Biopharma Inc   10.80 $ 170.301  Millions$ 15.774  Millions
Virios Therapeutics Inc   10.77 $ 5.249  Millions$ 0.487  Millions
Xencor Inc  10.77 $ 571.176  Millions$ 53.041  Millions
Xenetic Biosciences Inc   10.53 $ 11.257  Millions$ 1.069  Millions
Actinium Pharmaceuticals Inc   10.50 $ 85.596  Millions$ 8.150  Millions
Milestone Pharmaceuticals inc   10.45 $ 84.797  Millions$ 8.114  Millions
Structure Therapeutics Inc   10.45 $ 209.959  Millions$ 20.091  Millions

Date modified: 2023-11-03T15:10:19+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com